Key Points
- Director Luke Evnin sold 60,547 shares of Werewolf Therapeutics on June 8 at an average price of $0.40, worth about $24,219. The sale was made under a pre-arranged Rule 10b5-1 plan, leaving him with 377,211 shares.
- Evnin has been selling heavily in recent days, with multiple additional transactions in late May and early June, including several large sales of tens of thousands of shares each. The recent sales reduced his ownership by 13.83% in the latest transaction alone.
- Werewolf Therapeutics shares remain under pressure, opening at $0.38 with a market cap of $18.56 million and trading near their 52-week low of $0.37. Analysts currently have a Hold consensus rating and a $3.75 price target, while the company recently reported a smaller-than-expected quarterly loss.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 60,547 shares of the firm's stock in a transaction on Monday, June 8th. The stock was sold at an average price of $0.40, for a total value of $24,218.80. Following the completion of the transaction, the director directly owned 377,211 shares of the company's stock, valued at approximately $150,884.40. This trade represents a 13.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Friday, June 5th, Luke Evnin sold 24,946 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.40, for a total value of $9,978.40.
- On Thursday, June 4th, Luke Evnin sold 20,072 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.44, for a total value of $8,831.68.
- On Wednesday, June 3rd, Luke Evnin sold 29,749 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total value of $12,494.58.
- On Tuesday, June 2nd, Luke Evnin sold 29,595 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $13,317.75.
- On Monday, June 1st, Luke Evnin sold 80,459 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total value of $37,815.73.
- On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total value of $14,650.20.
- On Thursday, May 28th, Luke Evnin sold 27,698 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.46, for a total value of $12,741.08.
- On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.48, for a total value of $38,808.96.
- On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total value of $31,936.50.
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $39,341.25.
Werewolf Therapeutics Stock Performance
Shares of NASDAQ HOWL opened at $0.38 on Tuesday. The stock has a market cap of $18.56 million, a PE ratio of -0.31 and a beta of 0.29. The business has a fifty day moving average of $0.70 and a two-hundred day moving average of $0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.37 and a 52-week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.04. Analysts predict that Werewolf Therapeutics, Inc. will post -1.08 earnings per share for the current year.
Hedge Funds Weigh In On Werewolf Therapeutics
A number of large investors have recently modified their holdings of HOWL. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $409,000. Renaissance Technologies LLC lifted its position in shares of Werewolf Therapeutics by 48.6% during the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company's stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Werewolf Therapeutics during the third quarter worth approximately $304,000. Vanguard Group Inc. lifted its position in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock worth $2,774,000 after purchasing an additional 109,796 shares in the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $113,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
HOWL has been the subject of a number of analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut Werewolf Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $3.75.
Check Out Our Latest Analysis on HOWL
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
